The Technical Analyst
Actinium Pharmaceuticals [ATNM]
Exchange: AMEX Industry: Biotechnology
Actinium Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.91% $8.73
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 260.01 mill |
| EPS: | -1.710 |
| P/E: | -5.11 |
| Earnings Date: | Aug 12, 2024 |
| SharesOutstanding: | 29.78 mill |
| Avg Daily Volume: | 0.391 mill |
| RATING 2024-05-10 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.11 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.11 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.80 (-67.92%) $-5.93 |
| Date: 2024-05-12 |
| Expected Trading Range (DAY) |
|---|
|
$ 8.09 - 9.35 ( +/- 7.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-28 | Nicholson, C. David | Buy | 70 311 | Stock Option (Right to Buy) |
| 2023-12-28 | Steinhart Richard I | Buy | 70 311 | Stock Option (Right to Buy) |
| 2023-12-28 | O'loughlin Steve | Buy | 253 123 | Stock Option (Right to Buy) |
| 2023-12-28 | Shetty Ajit | Buy | 70 311 | Stock Option (Right to Buy) |
| 2023-12-28 | Seth Sandesh | Buy | 984 367 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 100 transactions |
| Buy: 13 159 883 | Sell: 1 707 212 |
Forecast:
16:00 - $8.73
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.73
Forecast 2: 16:00 - $8.73
Forecast 3: 16:00 - $8.73
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.73 (-1.91% ) |
| Volume | 0.196 mill |
| Avg. Vol. | 0.391 mill |
| % of Avg. Vol | 50.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATNM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Latest Press Releases
2024-05-07 08:00:00 - Press Release
Actinium Announces Kol Webinar To Highlight Recently Announced Iomab-act Trial With Leading Fda Approved Commercial Car T-cell Therapy Being Led By The University Of Texas Southwestern
Dr. farrukh awan, professor of medicine, division of hematology oncology at university of texas southwestern and principal investigator for the trial to join actinium management for webinar expansion of iomab-act program with commercial car-t supported by ongoing mskcc clinical trial with success implying a potential billion-dollar market opportunity in lymphodepletion webinar to be held on monday, may 20 th at 8:00 am et new york , may 7, 2024 /prnewswire/ -- actinium pharmaceuticals, inc. (nyse american: atnm) (actinium or the company), a leader in the development of antibody radiation conjugates (arcs) and other targeted radiotherapies, today announced it will host a kol call on monday, may 20, 2024, at 8:00 am et to provide updates and highlight its recently announced clinical trial to study iomab-act with a leading fda approved car-t cell therapy at the university of texas southwestern (utsw)...
2024-04-18 08:00:00 - Press Release
Actinium Highlights Ability Of Iomab-b To Overcome High-risk Tp53 Mutation Resulting In Significant Improvement In Overall Survival In Patients With Active Relapsed Refractory Aml At The European Bone Marrow Transplant Annual Meeting
-- iomab-b led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of tp53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia -- median overall survival of 5.49 months observed in patients with a tp53 mutation receiving an iomab-b led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive iomab-b (hazard ratio=0.23, p=0.0002) new york , april 18, 2024 /prnewswire/ -- actinium pharmaceuticals, inc. (nyse american: atnm) (actinium or the company), a leader in the development of antibody radiation conjugates (arcs) and other targeted radiotherapies, today announced that results from the phase 3 sierra trial of iomab-b were presented in an oral presentation at the 50th annual european bone marrow transplant society meeting (ebmt) held in glasgow, scotland on april 14-17...
2024-04-01 08:00:00 - Press Release
Actinium Announces Iomab-b Phase 3 Sierra Trial Results Demonstrating Survival Benefit In High-risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With Tp53 Mutations Accepted For Oral Presentation At The 50th European Bone Marrow Transplant Annual Meeting
- the sierra results demonstrate iomab-b's ability to overcome the negative impact of a tp53 mutation in patients who otherwise would have limited treatment options and dismal prognosis - represents the eleventh oral presentation of the phase 3 sierra results demonstrating continued recognition of the high potential for iomab-b led allogeneic bone marrow transplant by the bone marrow transplant community new york , april 1, 2024 /prnewswire/ -- actinium pharmaceuticals, inc. (nyse american: atnm) (actinium or the company), a leader in the development of antibody radiation conjugates (arcs) and other targeted radiotherapies, today announced that results from the phase 3 sierra trial of iomab-b in patients with a tp53 mutation have been accepted for oral presentation at the 50th annual meeting of the european bone marrow transplant society (ebmt) being held april 14 – 17, 2024, in glasgow, scotland...
2024-03-26 07:18:00 - Press Release
Actinium Announces Clinical Trial To Study Iomab-act Targeted Radiotherapy Conditioning With Leading Fda Approved Commercial Car T-cell Therapy
Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with car t-cell therapy a multi-billion market with six fda approved therapies totaling sales over $3.5 billion in 2023 and cell and gene therapies forecasted to reach over ninety-thousand patients annually by 2030 iomab-act is the first targeted radiotherapy agent intended to be used to condition patients for cell and gene therapies to replace the need for non-targeted chemotherapy iomab-act clinical data to date shows car t-cell persistence and ability to deplete targeted immune cells including lymphocytes resulting in negligible rates of car-t toxicities icans and crs new york , march 26, 2024 /prnewswire/ -- actinium pharmaceuticals, inc...
2024-03-14 02:00:00 - Press Release
Pantera Signs A Second Agreement For The Supply Of Actinium-225
Pantera's continues to deploy its strategy to become a market leader into the production and distribution of ac225
Latest News
2024-05-12 09:32:38 - Seeking Alpha
A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising results in clinical trials, increasing survival rates for elderly patients and targeting specific leukemia-related antigens. Strategic partnerships, particularly with Immedica AB for the EUMENA market, aim to strengthen Actinium's global market presence.
2024-04-15 12:54:18 - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
2024-03-15 06:15:00 - InvestorPlace
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
Few stock sectors offer soar-or-sink possibilities like biotechnology stocks do. If you're in the market for an intriguing biotech pick and can manage high risk, take a look at Actinium Pharmaceuticals (NYSEAMERICAN: ATNM )stock.
2024-02-25 13:37:41 - InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
2023-11-03 18:08:52 - Seeking Alpha
Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of findings in patients with TP53 mutation, showing improved overall survival with Iomab-B. Actinium Pharmaceuticals has a relatively stable position with $83 million in cash and 6 more quarters of cash on hand, but may need to tie a BLA submission with a public offering.
2023-09-15 19:02:20 - Seeking Alpha
Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?
Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of success at the regulatory level. No respect from the market means Actinium could be in a good position for upward movement.
2023-02-24 14:16:36 - Investors Business Daily
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Actinium has lofty ambitions to change the landscape of leukemia treatment. But ATNM stock cratered this week on final-phase test results.
2023-02-14 07:30:00 - PRNewsWire
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK , Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19, 2023 at the World Center Marriott in Orlando, Florida...
2023-01-10 04:23:47 - Seeking Alpha
Actinium Pharmaceuticals: Prep For February
Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators.
2022-10-31 12:12:59 - Market Watch
Actinium's stock jumps 22% on new data for its acute myeloid leukemia therapy
Shares of Actinium Pharmaceuticals Inc. ATNM, +24.20% were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for relapsed or refractory acute myeloid leukemia. Actinium said it plans to share additional clinical data by the end of the year.